Vyant Bio, Inc. (VYNT)

Market Cap	1.08M
Revenue (ttm)	666,000
Net Income (ttm)	-28.71M
Shares Out	6.33M
EPS (ttm)	-4.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,080
Open	0.177
Previous Close	0.167
Day's Range	0.170 - 0.180
52-Week Range	0.141 - 3.000
Beta	0.55
Analysts	Hold
Price Target	n/a
Earnings Date	Aug 29, 2023

About VYNT

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 5, 2013
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: VYNT

Financial Performance

In 2022, Vyant Bio's revenue was $666,000, a decrease of -41.99% compared to the previous year's $1.15 million. Losses were -$22.69 million, -50.78% less than in 2021.